Driving smarter investment in women’s health

Tern plc

The FemHealth Integrates Conference in Manchester created a dynamic space where innovation met necessity, shining a light on the systemic barriers that continue to impact women’s health outcomes. Voices from across healthcare, investment, research and technology came together to map the future of women’s health, highlighting the urgency for smarter strategies, deeper representation and unified thinking. It became clear that the next frontier in women’s health will be defined by the intelligent application of data, greater inclusivity and targeted investment.

One of the most pressing issues discussed was the stark regional divide in healthcare outcomes across England. Women living in the North continue to face poorer health compared to those in the South, a disparity driven by longstanding inequalities in resources, access and support. The conference highlighted the vital role of innovation hubs like Bruntwood SciTech in addressing these gaps and the importance of regional collaboration to even out healthcare delivery across the country.

The conversation around clinical trials revealed the progress made but also exposed how far there is still to go. Although policies have shifted to include women in research since the late 20th century, trial demographics remain heavily skewed towards men. Some studies still feature a staggering imbalance of one woman to fifty men. Smarter, more inclusive trial designs and outreach strategies are critical, as is the application of advanced data science to ensure outcomes truly reflect the diverse real-world population. The opportunities for transformation here are both vast and necessary.

The issue of investment inequality was equally stark. With only 15% of angel investors being women and the majority based in London, innovation outside the capital struggles to attract the funding it needs. This imbalance continues to limit the growth of women-led and female-focused health innovations, particularly within FemTech. However, shifting political landscapes, especially in the US, suggest new windows are opening for international investors ready to recognise the value in backing female founders. For investors, the message is clear—funding women’s health is not only an ethical choice but a strategic advantage.

The limitations caused by siloed health data were also sharply in focus. Women’s health information is often compartmentalised by life stage, failing to capture the continuous and connected nature of the female health journey. There is a massive opportunity for Healthcare Marketers and strategists to utilise AI and unified data systems to map the full patient experience, leading to more nuanced and personalised solutions. Investment in integrated approaches, as supported by findings from The Lancet Commission, promises profound impacts on morbidity, mortality and economic growth.

Cultural transformation was another standout theme. Organisations across the healthcare sector are redefining internal cultures through commitments to equal parental leave, transparent pay structures and stronger workplace equity. These changes are not mere corporate niceties; they reflect a deeper brand authenticity that resonates with patients and consumers alike. In a healthcare environment increasingly driven by trust and personal values, how a company operates internally is becoming just as important as the solutions it provides externally.

For those working in Healthcare Marketing and investment, the signals are loud and clear. The future of women’s health demands strategies informed by life journeys rather than symptoms, shaped by real-world data rather than assumptions, and delivered by organisations that reflect the diversity they aim to serve. The foundations have been laid, and the insights from FemHealth Integrates confirm that the path forward is rich with opportunity for those bold enough to build it.

Talking Medicines is a leading innovator in patient-centric data science, dedicated to transforming pharmaceutical marketing through real-world patient insights powered by AI. Their solutions empower companies to better understand patient journeys and create truly effective healthcare communications.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search